Increased arterial stiffness in resistant hypertension is associated with inflammatory biomarkers

Blood Pressure

Volumn 24, Issue 1, 2015, Pages 7-13

  Barbaro, Natália Ruggeri ^a   Fontana, Vanessa ^a   Modolo, Rodrigo ^a   De Faria, Ana Paula ^a   Sabbatini, Andrea Rodrigues ^a   Fonseca, Francisco Helfenstein ^b   Anhê, Gabriel F ^a   Moreno, Heitor ^a  

^a UNIVERSITY OF CAMPINAS   (Brazil)

^b FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Arterial stiffness; Inflammatory cytokines; Pulse wave velocity; Resistant hypertension

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; C REACTIVE PROTEIN; CALCIUM CHANNEL BLOCKING AGENT; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SPIRONOLACTONE; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; AUTACOID; BIOLOGICAL MARKER; CYTOKINE;

ADULT; ANTIHYPERTENSIVE THERAPY; ARTERIAL STIFFNESS; ARTICLE; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE MONITORING; BORDERLINE HYPERTENSION; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; CYTOKINE RELEASE; DIASTOLIC BLOOD PRESSURE; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PULSE PRESSURE; PULSE WAVE; RESISTANT HYPERTENSION; SYSTOLIC BLOOD PRESSURE; AGED; BLOOD; CLINICAL TRIAL; COMPARATIVE STUDY; HYPERTENSION; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY;

ADULT; AGED; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CYTOKINES; FEMALE; HUMANS; HYPERTENSION; INFLAMMATION MEDIATORS; MALE; MIDDLE AGED; VASCULAR STIFFNESS;

EID: 84921441065     PISSN: 08037051     EISSN: 16511999     Source Type: Journal    
DOI: 10.3109/08037051.2014.940710     Document Type: Article

References (38)

1. Calhoun DA, Jones D, Textor S, Goff DC, Murphy TP, Toto RD, et al. Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension. 2008;51:1403-1419.
2. de Souza WA, Yugar-Toledo JC, Bergsten-Mendes G, Sabha M and Moreno H, Jr. Effect of pharmaceutical care on blood pressure control and health-related quality of life in patients with resistant hypertension. Am J Health Syst Pharm. 2007;64:1955-1961.
3. Martins LC, Figueiredo VN, Quinaglia T, Boer-Martins L, Yugar-Toledo JC, Martin JF, et al. Characteristics of resistant hypertension: Ageing, body mass index, hyperaldosteronism, cardiac hypertrophy and vascular stiffness. J Hum Hypertens. 2011;25:532-538.
4. Acelajado MC, Pisoni R, Dudenbostel T, Dell'Italia LJ, Cartmill F, Zhang B, et al. Refractory hypertension: Definition, prevalence, and patient characteristics. J Clin Hypertens (Greenwich). 2012;14:7-12.
5. Mancia G, Laurent S, Agabiti-Rosei E, Ambrosioni E, Burnier M, Caulfield MJ, et al. Reappraisal of European guidelines on hypertension management: A European Society of Hypertension Task Force document. J Hypertens. 2009;27:2121-2158.
6. Laurent S, Boutouyrie P, Asmar R, Gautier I, Laloux B, Guize L, et al. Aortic stiffness is an independent predictor of all-cause and cardiovascular mortality in hypertensive patients. Hypertension. 2001;37:1236-1241.
7. Mahmud A and Feely J. Arterial stiffness is related to systemic inflammation in essential hypertension. Hypertension. 2005;46:1118-1122.
8. Chappell DC, Varner SE, Nerem RM, Medford RM and Alexander RW. Oscillatory shear stress stimulates adhesion molecule expression in cultured human endothelium. Circ Res. 1998;82:532-539.
9. Bautista LE, Vera LM, Arenas IA and Gamarra G. Independent association between inflammatory markers (C-reactive protein, interleukin-6, and TNF-alpha) and essential hypertension. J Hum Hypertens. 2005;19:149-154.
10. Mauno V, Hannu K and Esko K. Proinflammation and hypertension: A population-based study. Mediators Inflamm. 2008;2008:619704.
11. Salles GF, Fiszman R, Cardoso CR and Muxfeldt ES. Relation of left ventricular hypertrophy with systemic inflammation and endothelial damage in resistant hypertension. Hypertension. 2007;50:723-728.
12. Barhoumi T, Kasal DA, Li MW, Shbat L, Laurant P, Neves MF, et al. T regulatory lymphocytes prevent angiotensin II-induced hypertension and vascular injury. Hypertension. 2011;57:469-476.
13. Brili S, Tousoulis D, Antoniades C, Vasiliadou C, Karali M, Papageorgiou N, et al. Effects of ramipril on endothelial function and the expression of proinflammatory cytokines and adhesion molecules in young normotensive subjects with successfully repaired coarctation of aorta: A randomized cross-over study. J Am Coll Cardiol. 2008;51:742-749.
14. Luther JM, Gainer JV, Murphey LJ, Yu C, Vaughan DE, Morrow JD, et al. Angiotensin II induces interleukin-6 in humans through a mineralocorticoid receptor-dependent mechanism. Hypertension. 2006;48:1050-1057.
15. Takagi H, Mizuno Y, Yamamoto H, Goto SN and Umemoto T. Effects of telmisartan therapy on interleukin-6 and tumor necrosis factor-alpha levels: A meta-analysis of randomized controlled trials. Hypertens Res. 2012;36:368-373.
16. Sackett DL, Haynes RB, Gibson ES, Hackett BC, Taylor DW, Roberts RS, et al. Randomised clinical trial of strategies for improving medication compliance in primary hypertension. Lancet. 1975;1:1205-1207.
17. Morisky DE, Green LW and Levine DM. Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care. 1986;24:67-74.
18. Duprez DA and Cohn JN. Arterial stiffness as a risk factor for coronary atherosclerosis. Curr Atheroscler Rep. 2007;9:139-144.
19. Van Bortel LM, Laurent S, Boutouyrie P, Chowienczyk P, Cruickshank JK, De Backer T, et al. Expert consensus document on the measurement of aortic stiffness in daily practice using carotid-femoral pulse wave velocity. J Hypertens. 2012;30:445-448.
20. Figueiredo VN, Yugar-Toledo JC, Martins LC, Martins LB, de Faria AP, de Haro Moraes C, et al. Vascular stiffness and endothelial dysfunction: Correlations at different levels of blood pressure. Blood Press. 2012;21:31-38.
21. Pabuccu T, Baris N, Ozpelit E, Akdeniz B and Guneri S. The relationship between resistant hypertension and arterial stiffness. Clin Exp Hypertens. 2012;34:57-62.
22. Protogerou A, Blacher J, Stergiou GS, Achimastos A and Safar ME. Blood pressure response under chronic antihypertensive drug therapy: The role of aortic stiffness in the REASON (Preterax in Regression of Arterial Stiffness in a Controlled Double-Blind) study. J Am Coll Cardiol. 2009;53:445-451.
23. Pietri P, Vyssoulis G, Vlachopoulos C, Zervoudaki A, Gialernios T, Aznaouridis K, et al. Relationship between low-grade inflammation and arterial stiffness in patients with essential hypertension. J Hypertens. 2006;24:2231-2238.
24. Kaptoge S, Di Angelantonio E, Pennells L, Wood AM, White IR, Gao P, et al. C-reactive protein, fibrinogen, and cardiovascular disease prediction. N Engl J Med. 2012;367:1310-1320.
25. Magen E, Mishal J, Paskin J, Glick Z, Yosefy C, Kidon M, et al. Resistant arterial hypertension is associated with higher blood levels of complement C3 and C-reactive protein. J Clin Hypertens (Greenwich). 2008;10:677-683.
26. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM, Jr., Kastelein JJ, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195-2207.
27. Takahashi H, Nishimura M, Sakamoto M, Ikegaki I, Nakanishi T and Yoshimura M. Effects of interleukin-1 beta on blood pressure, sympathetic nerve activity, and pituitary endocrine functions in anesthetized rats. Am J Hypertens. 1992;5:224-229.
28. Ito H, Ohshima A, Tsuzuki M, Ohto N, Takao K, Hijii C, et al. Association of serum tumour necrosis factor-alpha with serum low-density lipoprotein-cholesterol and blood pressure in apparently healthy Japanese women. Clin Exp Pharmacol Physiol. 2001;28:188-192.
29. Filho AG, Kinote A, Pereira DJ, Renno A, dos Santos RC, Ferreira-Melo SE, et al. Infliximab prevents increased systolic blood pressure and upregulates the AKT/eNOS pathway in the aorta of spontaneously hypertensive rats. Eur J Pharmacol. 2013;700:201-209.
30. Rosa AC, Rattazzi L, Miglio G, Collino M and Fantozzi R. Angiotensin II induces tumor necrosis factor-alpha expression and release from cultured human podocytes. Inflamm Res. 2012;61:311-317.
31. Johansen NB, Vistisen D, Brunner EJ, Tabak AG, Shipley MJ, Wilkinson IB, et al. Determinants of aortic stiffness: 16-year follow-up of the Whitehall II study. PLoS One. 2012;7:e37165.
32. Vlachopoulos C, Dima I, Aznaouridis K, Vasiliadou C, Ioakeimidis N, Aggeli C, et al. Acute systemic inflammation increases arterial stiffness and decreases wave reflections in healthy individuals. Circulation. 2005;112:2193-2200.
33. Briet M and Schiffrin EL. Vascular actions of aldosterone. J Vasc Res. 2012;50:89-99.
34. Hingorani AD, Cross J, Kharbanda RK, Mullen MJ, Bhagat K, Taylor M, et al. Acute systemic inflammation impairs endothelium-dependent dilatation in humans. Circulation. 2000;102:994-999.
35. Tilg H, Trehu E, Atkins MB, Dinarello CA and Mier JW. Interleukin-6 (IL-6) as an anti-inflammatory cytokine: Induction of circulating IL-1 receptor antagonist and soluble tumor necrosis factor receptor p55. Blood. 1994;83:113-118.
36. Didion SP, Kinzenbaw DA, Schrader LI, Chu Y and Faraci FM. Endogenous interleukin-10 inhibits angiotensin II-induced vascular dysfunction. Hypertension. 2009;54:619-624.
37. Fonseca HA, Fonseca FA, Monteiro AM, Bianco HT, Boschcov P, Brandao SA, et al. Obesity modulates the immune response to oxidized LDL in hypertensive patients. Cell Biochem Biophys. 2013.
38. Moreno H, Jr., Coca A. Resistant and refractory hypertension: Reflections on pathophysiology and terminology. Blood Press. 2012;21:209-210.